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ABSTRACT: Background: Although primarily a neuro-
degenerative process, there is increasing awareness of
peripheral disease mechanisms in Parkinson’s disease. To
investigate disease processes in accessible patient cells,
we studied peripheral blood mononuclear cells in recently
diagnosed PD patients and rapid eye movement-sleep
behavior disorder patients who have a greatly increased
risk of developing PD. We hypothesized that peripheral
blood mononuclear cells may recapitulate cellular pathol-
ogy found in the PD brain and investigated these cells for
mitochondrial dysfunction and oxidative stress.
Methods: Peripheral blood mononuclear cells were iso-
lated and studied from PD patients, rapid eye movement-
sleep behavior disorder patients and age- and sex-
matched control individuals from the well-characterized
Oxford Discovery cohort. All participants underwent thor-
ough clinical assessment.
Results: Initial characterization showed that PD patients
had elevated levels of CD14 + monocytes and mono-
cytes expressing C-C motif chemokine receptor 2. Mito-
chondrial dysfunction and oxidative stress were increased
in PD patient peripheral blood mononuclear cells, with ele-
vated levels of mitochondrial reactive oxygen species spe-
ciﬁcally in patient monocytes. This was combined with
reduced levels of the antioxidant superoxide dismutase in
blood cells from PD patients and, importantly, also in rapid
eye movement-sleep behavior disorder patients. This mito-
chondrial dysfunction was associated with a concomitant
increase in glycolysis in both PD and rapid eye movement-
sleep behavior disorder patient blood cells independent of
glucose uptake or monocyte activation.
Conclusions: This work demonstrates functional bioen-
ergetic deﬁcits in PD and rapid eye movement-sleep
behavior disorder patient blood cells during the early
stages of human disease. © 2018 The Authors. Move-
ment Disorders published by Wiley Periodicals, Inc. on
behalf of International Parkinson and Movement Disorder
Society.
Key Words: Parkinson’s disease; peripheral blood
mononuclear cells; mitochondrial dysfunction; glycolysis;
REM-sleep behavior disorder
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Most cases of Parkinson’s disease (PD) are idiopathic,
and there is as yet no diagnostic or predictive molecular
marker of disease. It has been estimated that at the
point of PD diagnosis, there is already signiﬁcant dopa-
minergic neuron loss and associated pathology in the
substantia nigra, making it difﬁcult to implement
disease-modifying treatments.1 There is now substantial
evidence that one such group of people who may bene-
ﬁt from disease-modifying treatments are patients with
idiopathic rapid eye movement (REM)-sleep behavior
disorder (RBD), up to 80% of whom will progress to
PD or a related synucleinopathy, forming a highly
enriched PD at-risk group.2–4
As a source of patient tissue in which to study early
disease processes, blood samples are easily accessible
and cost-efﬁcient and can be obtained with low risk to
the patient. Peripheral blood cells perform many of the
fundamental cellular processes that are perturbed in
PD, and we hypothesized that they may recapitulate the
cellular pathology observed in the PD brain. Several
lines of evidence indicate strong immune involvement
in PD pathogenesis, including neuroinﬂammation in PD
postmortem brains shown by immunochemistry and
PET imaging.5–7 Several of the mutations that give rise
to PD are found in genes that are highly expressed by
immune cells including the relatively common genetic
mutations in LRRK2 and GBA and the meta-GWAS
hit HLA-DQB1.8–10 It is less clear, however, whether
PD-related neuronal pathology is reﬂected or can be
detected in peripheral blood cells and whether detection
will be sensitive enough to provide a practical indica-
tion of early disease processes and progression.
The current article describes a functional study in
peripheral blood mononuclear cells (PBMCs) from PD
patients, RBD patients, and control individuals from
the well-characterized longitudinal Oxford Discovery
cohort.11 Focusing on a key pathological mechanism
that has been shown to play a role in dopaminergic
neuron death, we tested the hypothesis that mitochon-
drial and bioenergetic changes would be present in PD
patient peripheral blood cells. Mitochondrial dysfunc-
tion and oxidative stress have been shown to be major
pathological mechanisms in PD models ranging from
neurotoxin and genetic rodent models to iPSC neu-
rons.12,13 Indeed, analysis of Parkinson’s patient and
aged human postmortem brain tissue has revealed the
presence of oxidative species, decreased levels of antiox-
idants, and elevated markers of oxidative damage
and mitochondrial DNA mutations.12,14,15 We
assessed mitochondrial health using ﬂow cytometry
for high-throughput analysis of large numbers of cells
and an Extracellular Flux Analyzer to measure oxy-
gen consumption and glycolysis rates.16 In this study
we demonstrate functional bioenergetic changes in




This work was carried out in agreement with the
Declaration of Helsinki with the approval of the local
National Health Service ethics committee and Univer-
sity of Oxford Research Ethics Committee and with
written informed consent from every participant. Partic-
ipants were recruited through the Oxford Parkinson
Disease Center Discovery Cohort.11,17,18 PD patients
were recently diagnosed according to the UK Parkin-
son’s Disease Society Brain Bank criteria. RBD patients
were recruited from sleep clinics at John Radcliffe Hos-
pital in Oxford and Papworth Hospital in Cambridge.
Idiopathic RBD diagnosis was made as previously
described,17 according to standard criteria of the Inter-
national Classiﬁcation of Sleep Disorders II following
overnight polysomnograph. RBD patients who already
had dementia, mild cognitive impairment, or parkin-
sonism at baseline were excluded. Age- and sex-
matched control participants were recruited from the
same geographical areas and were frequently spouses of
patients. Blood samples were collected from individuals
who came into the clinic between March 2014 and
December 2016 (Table S1). Samples for all experiments
were matched across disease groups with no signiﬁcant
differences in age, sex, or blood sample processing time.
An outline of the principal experiments is provided in
Figure S1, where we indicate the number of donor sam-
ples used for each experiment. Initial ﬂow-cytometric
experiments were performed with large numbers of
donor samples (n = 50); however, because of reduced
availability of samples, subsequent experiments were
performed with smaller sample sizes. Patient samples
used in these subsequent analyses were selected based
on age- and sex-matching criteria for the control sam-
ples available and were not selected based on pathologi-
cal or biochemical criteria.
PBMC Isolation
Fifteen milliliters of blood from each participant was
collected in K2-ethylenediaminetetraacetic acid-coated
vacutainer tubes (BD Biosciences, San Jose, CA;
367839). PBMCs were isolated from whole blood using
a standard Ficoll-Paque Plus gradient solution and cen-
trifugation procedure. Brieﬂy, 15 mL of blood mixed
with 10 mL of phosphate-buffered saline (PBS) pH 7.4
(Gibco, Waltham, MA; 10010023) was slowly pipetted
on top of 15 mL of Ficoll-Paque Plus (GE Healthcare,
Amersham, UK; 17-1440-03) gradient solution in a
50-mL Leucosep tube (Greiner Bio-One, Stonehouse,
UK; GREI227290UK) and centrifuged for 10 minutes at
1000g with minimal acceleration and deceleration. The
“buffy-coat” layer of PBMCs was aspirated into a new
50-mL Falcon tube and washed 3 times with 40 mL of
PBS, centrifuging at 300g for 10 minutes with normal
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acceleration/deceleration settings. Cells were cryopre-
served in 0.5 mL of PBS and 0.5 mL of freeze mix (fetal
bovine serum containing 20% dimethylsulfoxide).
Flow Cytometry
On the day prior to ﬂow-cytometric analysis, cells
were plated in Roswell Park Memorial Institute media
(Gibco) containing 10% fetal calf serum (FCS) and 1%
L-glutamine into round bottom 96-well plates (CLS3799;
Sigma, Haverhill, UK). For surface antibody staining,
cells were blocked for 10 minutes at 4C with 100 μL of
PBS containing 5% FCS and 1% bovine serum albumin.
Live/Dead Fixable Near-IR Dead Cell Stain (L10119;
Molecular Probes, Waltham, MA) was used at 1:2000
(15 minutes at 4C). Cells were incubated with surface
marker antibodies (Table S2) for 20 minutes at
4C. Data were acquired using a Becton Dickinson LSR
II ﬂow cytometer and analyzed using FlowJo vX.0.7.
Populations of interest were gated using a combination
of unstained, ﬂuorescence-minus-one and internal nega-
tive population controls as appropriate (Fig. S2).
MitoSox and MitoTracker
Cells were incubated with 5 μM MitoSox Red
(Invitrogen, Waltham, MA) and 100 nM MitoTracker
Deep Red (Invitrogen) for 30 minutes at 37C. PBS was
added to compensation controls and unstained sample.
Cells were labeled with Live/Dead dye and analyzed by
ﬂow cytometry as described above. Rotenone-treated
cells (50 μM, 1.5 hours) were used as an internal con-
trol for technical variability between experiments.
Tetramethylrhodamine Methyl Ester
Two wells were plated per sample, and 1 well was
treated with 50 μM carbonyl cyanide m-chlorophenyl
hydrazone (CCCP) mitochondrial uncoupler for 1 hour.
All cells were incubated with 100 nM tetramethylrho-
damine methyl ester (TMRM; Invitrogen, Waltham,
MA) for 30 minutes at 37C. Mitochondrial membrane
potential was calculated as basal minus CCCP-treated.
Glucose Uptake and GLUT1 Surface
Expression
PBMCs were incubated with ﬂuorescent D-glucose ana-
logue 2-NBDG (Molecular Probes, Waltham, MA) at
25 μg/mL for 30 minutes. GLUT1 was assessed using
GLUT1.RBD (Metafora Biosystems, Evry, France) accord-
ing to the manufacturer’s instructions at 1:100. Binding of
the RBD was visualized using R-phycoerythrin (PE) rat
antimouse IgG1 (550083; BD Pharmingen, San Jose, CA).
Antioxidant Enzyme Activity Assays
Total SOD activity was measured using a Superoxide
Dismutase Assay Kit (706002; Cayman Chemical Com-
pany, Ann Arbor, MI). Catalase activity was measured
using a Catalase Assay Kit (707002; Cayman Chemical
Company).
Reverse Transcription and Quantitative Real-
Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction
(qPCR) was carried out using an RNeasy Micro Kit
(Qiagen, Manchester, UK), SuperScript III Reverse
Transcriptase (Invitrogen), and Fast SYBR Green
(Invitrogen) and analyzed using an Applied Biosystems
StepOnePlus Real-Time PCR System. Table S3 lists the
primers used. Gene expression was quantiﬁed from
samples run in triplicate using the 2-(ΔΔCT) method,19
normalized to the mean of 3 endogenous control genes
— β-actin, GAPDH, and β2-microglobulin — and then
normalized to the mean of the healthy control samples.
Seahorse Extracellular Flux Analyzer
Oxygen consumption rate (OCR) and extracellular
acidiﬁcation rate (ECAR) were measured using a Sea-
horse XFe96 Extracellular Flux Analyzer (Seahorse Bio-
sciences, Billerica, MA) according to the manufacturer’s
instructions. Experimental setup for PBMCs was based
on that in Jones et al,16 with minor adjustments. Cells
were sequentially treated with 0.5 μM oligomycin,
1 μM FCCP, 0.5 μM rotenone/antimycin A, and
50 mM 2-deoxyglucose. Data were normalized to DAPI
cell counts and then to the mean of the healthy control
samples. Analysis was performed using Wave software.
Fluidigm Gene Expression Analysis
PBMCs were sorted using a BD FACSAria III based on
CD14 surface marker expression (CD14-PE; Miltenyi Bio-
tec, Bisley, UK); monocytes were gated for high CD14
expression, and lymphocytes were selected based on lack of
CD14 expression. Duplicate wells of 100 cells were sorted
for both monocytes and lymphocytes for each sample.
Reverse transcription, speciﬁc target ampliﬁcation, and
48.48 Dynamic Arrays (Fluidigm, Cambridge, UK) were
performed as previously described.20 A no-RT and no tem-
plate control was included in each experiment. Gene
expression was quantiﬁed using the 2-(ΔΔCT) method,19 nor-
malized to the mean of 2 endogenous control genes, β-actin
and β2-microglobulin, and then normalized to the internal
control sample that was run in each of 3 experiments.
Statistical Analysis
Graphing and statistical analysis were performed
using GraphPad Prism 6. Data are presented with each
point representing a participant sample and the number
of samples used in each experiment is indicated in the
ﬁgure legends. Outliers were identiﬁed by the ROUT
test (Q = 1%) and removed from analysis. Normality
was assessed using the D’Agostino & Pearson omnibus
normality test, and, according to this outcome, signiﬁcance
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was determined by the Mann-Whitney test or 1-way anal-
ysis of variance (ANOVA). A P < 0.05 was considered sig-
niﬁcant, except for the Fluidigm gene expression analysis.
Here, Bonferroni correction was used to adjust the signiﬁ-
cance thresholds for multiple comparisons (α = 0.001 for
monocytes; α = 0.002 for lymphocytes). This method
identiﬁed the same signiﬁcant results obtained using the
Benjamini-Hochberg procedure with a false discovery rate
of 0.1%. Experiments were performed using the largest
sample size possible (determined by availability of patient
samples) while maintaining age- and sex-matched groups.
Numbers are given in the ﬁgure legends.
Results
Parkinson’s Patients Have Increased
Frequency of CD14 + and CCR2 + Monocytes
To assess changes in PBMC populations within the
Oxford Discovery Cohort, we began by analyzing
PBMC subtypes with a panel of cell surface markers
(Table S2). Using ﬂow cytometry, we compared the rel-
ative frequencies of PBMC subtypes between 50 PD
patients and 50 age- and sex-matched controls. Interest-
ingly, a higher frequency of monocytes (identiﬁed as
CD14+) was found to be present in the PD patients
compared with controls (Fig. 1A). To further character-
ize this monocyte population, we looked at the nonclas-
sical monocyte marker CD16 (FcγIII receptor) and
2 receptors for chemokines known to be elevated in
PD: CCR2 (CD192) and CXCR3 (CD183).21 A higher
frequency of chemotactic CCR2 + monocytes was
observed for PD patients compared with controls,
whereas no differences in CD16 or CXCR3 monocyte
populations were found (Fig. 1B-E). Furthermore, there
was a signiﬁcant positive correlation between the fre-
quency of CCR2 + monocytes and disease duration
within PD patients (P = 0.0345) (Fig. 1C). These
changes in blood cell frequency were speciﬁc for innate
FIG. 1. PD patients have greater relative frequencies of monocytes (CD14+) and CCR2 + monocytes compared with controls. Flow cytometry was used to
assess the frequencies of different blood cell subtypes in PBMC samples from PD patients and matched controls. (A) CD14 + monocyte population of
PBMCs is larger in PD samples compared with controls. An increase in CCR2 + monocyte frequency was also evident in PD patients (B) and correlated with
disease duration (C). No difference was observed for CXCR3 + (D) or CD16 + (E) monocytes. (F, G) B- and T-lymphocyte populations do not differ between
control and PD samples (n = 50; analysis by Mann-Whitney test). Data are shown relative to an internal control sample run in each of 8 experiments, then
multiplied by the average frequency for the internal control sample to represent actual frequencies. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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immune cells, as no difference in frequency was
observed for the CD19 + B-cell and CD3 + T-cell
lymphocyte subtypes (Fig. 1F,G). Furthermore, the
CD8 marker of cytotoxic T cells and the chemokine
receptor CXCR3 were found to be similarly
expressed on CD3 + T cells, as were markers of
senescent (CD57+) and nonsenescent (CD28+) CD8 +
T cells (Fig. S3).
Parkinson’s Patient Monocytes Have Increased
Mitochondrial Reactive Oxygen Species and
Reduced Mitochondrial Content
Many lines of evidence point to mitochondrial dys-
function as a key mediator of neuronal death in PD.13
We investigated mitochondrial pathology in control and
PD patient peripheral monocytes, as well as lymphocytes
and total PBMCs, by measuring mitochondrial content
(MitoTracker) and mitochondrial reactive oxygen
species (ROS) production (MitoSox). In total PBMCs,
mitochondrial content and mitochondrial ROS produc-
tion were similar across patients and controls (n = 25;
Fig. 2A-C). However, the monocyte subset in PD
patients showed striking mitochondrial differences. In
PD patient monocytes, there was signiﬁcantly lower
mitochondrial content and higher levels of mitochondrial
ROS. Furthermore, when ROS levels were analyzed per
mitochondrial content (ie, MitoSox/MitoTracker), the
PD patient monocytes had even greater mitochondrial
ROS levels (Fig. 2D-F ).
Given this difference in controls versus patients, we
examined monocytes from REM-sleep behavior disor-
der (RBD) patients, who have a high risk of developing
PD. However, in this prodromal group we did not ﬁnd
evidence for reduced mitochondrial content or
increased mitochondrial ROS production in monocytes
(n = 18; Fig. 2G-I).
FIG. 2. Increased mitochondrial ROS and reduced mitochondrial content in PD patient monocytes. Levels of mitochondrial ROS production (MitoSox)
and mitochondrial content (MitoTracker) were assessed in control and PD patient PBMC samples by ﬂow cytometry. (A-C) Signiﬁcant differences were
not apparent in total PBMCs. (D-F ) However, in the monocyte subset, PD monocytes had greater mitochondrial ROS production and lower mitochon-
drial content compared with controls. Data are shown relative to rotenone-treated positive control (n = 25; analysis by Mann-Whitney test). (G-I) Mito-
chondrial ROS and content measured in controls and RBD patients who have a high risk of developing PD (n = 19 controls and 18 RBDs). [Color ﬁgure
can be viewed at wileyonlinelibrary.com]
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Reduced Expression and Function of
Superoxide Dismutase in PBMCs From
Parkinson’s and RBD Patients
As superoxide is the predominant mitochondrial-
generated ROS,22 we further investigated superoxide
regulation in PBMCs. Levels of superoxide are in part
regulated by the antioxidant enzyme superoxide dismu-
tase (SOD), which catalyzes the conversion of superox-
ide to oxygen and hydrogen peroxide. To assess whether
the increase in mitochondrial ROS in monocytes from
PD patients was accompanied by changes in SOD, we
looked at the expression of SOD in PBMCs. A reduction
in SOD1 transcript levels was observed for both PD and
RBD patient PBMCs compared with controls (Fig. 3A).
Furthermore, when we assessed the activity of total SOD
(SOD 1 and SOD 2) in PBMCs, we found a signiﬁcant
reduction in total SOD activity in individuals with RBD
compared with controls (Fig. 3B).
The hydrogen peroxide formed from superoxide by
SOD is then converted to oxygen and water by the anti-
oxidant enzyme catalase. We observed increased
expression of catalase in PBMCs only in RBD samples
compared with controls. No difference in catalase activ-
ity was observed between the control and either disease
state (Fig. 3C,D), highlighting a deﬁcit in SOD enzymes
in patient blood cells.
Levels of Glycolysis Are Higher in Both
Parkinson’s and RBD Patient PBMCs
Given the increase in mitochondrial ROS and reduced
mitochondrial content observed in PD patient mono-
cytes, we further investigated cellular bioenergetics by
measuring oxidative phosphorylation (OCR) and gly-
colysis (extracellular acidiﬁcation rate; ECAR) in
PBMCs from controls and PD and RBD patients with a
Seahorse XFe96 Extracellular Flux Analyzer.
There were no differences in oxygen consumption rates
between PBMCs from control and disease groups (Fig. S5).
Conversely, we observed a marked elevation in glycolysis
for both the PD and RBD patient groups compared with
controls, ﬁnding glycolysis, glycolytic capacity, and glyco-
lytic reserve all signiﬁcantly higher in PBMCs from PD and
RBD patients compared with controls (Fig. 4A-D). As
monocytes are known to have higher levels of glycolysis
than lymphocytes,23 we wished to determine whether higher
monocyte number may contribute to the increased glycolysis
observed in patient PBMCs. Parallel ﬂow-cytometric analy-
sis did not show a signiﬁcant difference in monocyte
FIG. 3. Reduced expression and function of superoxide dismutase (SOD) in disease compared with control PBMCs. (A) SOD1 mRNA expression in
PBMCs was quantiﬁed using reverse-transcriptase qPCR. SOD1 levels were signiﬁcantly lower in PD and RBD patient PBMCs compared with controls
(n ≥ 10). (B) Total SOD activity was signiﬁcantly lower in RBD patient PBMCs compared with controls; analysis by 1-way ANOVA (n ≥ 13). (C) RBD
patient PBMCs had higher catalase mRNA expression compared with controls (n ≥ 10); however no difference was found in catalase activity (D;
n = 18). [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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frequency between these control and patient PBMCs sam-
pled for the Seahorse Extracellular Flux Analyzer experi-
ment (n = 15), suggesting that the glycolysis phenotype
observed here may be a result of disease-related cellular
changes independent of increased numbers of monocytes.
To further investigate the increased glycolysis observed
in the PD and RBD patient PBMCs, we measured tran-
script levels of enzymes required for glycolysis and found
dysregulated expression of 2 glycolysis genes. Pyruvate
dehydrogenase kinase 1 (PDK1) was signiﬁcantly
reduced in PD patients compared with controls, and
lactate dehydrogenase B (LDHb) was found to be
reduced in both PD and RBD patients (Fig. 4E,F ).
We next studied glucose uptake by measuring cell
surface expression of GLUT-1 and the uptake of the
ﬂuorescent glucose analogue 2-NBDG. GLUT1 expres-
sion and 2-NBDG uptake were assessed for total
PBMCs, lymphocytes only, and monocytes only. No
signiﬁcant differences were found between disease
groups (Fig. S6), indicating that glucose uptake was not
driving the increased glycolysis observed for PD and
RBD patient PBMCs.
FIG. 4. Levels of glycolysis are increased in PD and RBD patient PBMCs compared with controls. (A-D) Control, PD, and RBD patient PBMCs were
analysed using a Seahorse Extracellular Flux Analyzer to measure glycolysis rates. (A) Average traces over time (green, controls; red, PD patients; blue,
RBD patients). Arrows indicate sequential injection of oligomycin, FCCP, antimycin A + rotenone, and 2-deoxyglucose. (B-D) Measures of glycolysis
(extracellular acidiﬁcation rate) were higher in the PBMCs of PD and RBD patients compared with age- and sex-matched controls. Data are from 3 inde-
pendent experiments normalized to the mean of the control values for each experiment (14 control, 15 PD, and 13 RBD samples; analysis by 1-way
ANOVA). (E, F ) Glycolysis genes pyruvate dehydrogenase kinase 1 (PDK1) and lactate dehydrogenase B (LDHB) were quantiﬁed using reverse-
transcriptase PCR in disease and control PBMCs; analysis by 1-way ANOVA.
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High-Throughput Gene Expression Analysis
Reveals Reduced COX4 Expression in RBD
Patient Monocytes and Lymphocytes
Monocytes are known to become more glycolytic
when they become “activated.”24 To assess the contri-
bution of monocyte activation to the high rates of gly-
colysis in PD and RBD patient PBMCs, high-
throughput gene expression analysis of monocytes
ﬂuorescence-activated cell sorted (FACS) from PBMC
samples was performed using a Fluidigm Dynamic
Array. This transcriptomic analysis did not ﬁnd evi-
dence for increased monocyte activation in PD or RBD
patients compared with controls based on expression of
several cytokines and chemokines, cell surface recep-
tors, complement components, and enzymes (Table S4),
indicating that the increased glycolysis is independent
of increased monocyte activation.
Using this high-throughput gene expression plat-
form we also analyzed a panel of glycolysis and oxi-
dative stress genes in FACS-sorted monocytes and
lymphocytes. The most striking gene expression dif-
ference between disease groups was observed in both
monocytes and lymphocytes. The RBD group had sig-
niﬁcantly lower expression of the mitochondrial
enzyme cytochrome c oxidase subunit IV isoform
1 (COX4) compared with both controls and PD
patients (Fig. 5), suggesting a unique change in
expression in a key gene for mitochondrial function
in RBD patients.
Discussion
This study has revealed differences in key cellular func-
tions in blood cells between PD and RBD patients and
healthy controls. Both PD and at-risk RBD patients exhib-
ited signiﬁcant increases in PBMC glycolysis and deﬁcits
in superoxide dismutase. In the monocyte subset in partic-
ular, PD patients exhibited increased mitochondrial ROS
and reduced mitochondrial content, in addition to an
increased frequency of chemotactic monocytes found in
PD patients.
The ﬁrst aim of this study was to characterize PBMC
subpopulations in PD patients compared with control
individuals. We found an altered monocyte subpopulation
in PD patients with, on average, a higher frequency of
total CD14 + monocytes and a higher frequency of
monocytes expressing the CCR2 receptor for monocyte
chemoattractant protein-1 (MCP-1 or CCL2). In addi-
tion, the CCR2 + monocyte population in PD patients
signiﬁcantly increased with disease duration. Together
with other studies,21,25 this work shows that the CCR2
chemokine receptor is speciﬁcally dysregulated in
monocytes in PD and is likely to play a role in the
immune component of PD. Monocytes expressing the
CCR2 chemokine receptor may be recruited into PD
brain tissue, as brain cells have been shown to produce
the CCR2 ligand MCP-1.26,27 If they are proinﬂamma-
tory, these monocytes may be detrimental to brain health;
however, more studies are required to investigate the role
of peripheral monocyte recruitment into the human brain
throughout disease progression. Increased monocyte fre-
quency may indicate dominance of the innate immune
system, which has been shown to occur with aging.28,29
Although a recent study by Cook et al (2017) did not ﬁnd
a signiﬁcant increase in CD14 + monocyte frequency in
PD patients (albeit with a smaller sample size), there was
a trend toward an increase. In addition, they observed a
decrease in T-cell frequency, corroborating the idea of
dominance of the innate immune system. In addition,
levels of the PD-related protein LRRK2 were found to
correlate with PD patient monocytes.8 Monocytes are cer-
tainly emerging as a key cell type conferring neurodegen-
erative disease risk, and several monocyte-speciﬁc genetic
disease variants are being identiﬁed.30,31
In addition to increased monocyte frequency, this study
also demonstrates monocyte-speciﬁc mitochondrial dys-
function in PD patients. Mitochondrial dysfunction has
FIG. 5. High-throughput gene expression analysis reveals COX4 gene expression changes for RBD patients in both monocytes and lymphocytes.
PBMCs were sorted for CD14 + monocytes and CD14- lymphocytes, and high-throughput gene expression was performed using a Fluidigm 48.48
Dynamic Array. Cytochrome c oxidase subunit IV isoform 1 (COX4) was signiﬁcantly reduced in both monocytes (A) and lymphocytes (B) for RBD
patients (15 controls, 16 PD patients, and 13 RBD patients). [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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been demonstrated in many PD models including human
neurons and ﬁbroblasts.13,32–34 We investigated whether
mitochondrial dysfunction and oxidative stress were also
detectable in easily accessible PBMCs from PD patients
and, importantly, RBD patients. We found a substantial
increase in mitochondrial ROS in monocytes of PD
patients. The accompanying reduction in mitochondrial
content suggests that there may be fewer functioning
mitochondria and may indicate a reduced capacity to
replace dysfunctional mitochondria. These perturbations
suggest mitochondrial dysfunction may contribute to
pathology.
These results expand on previous literature indicating
generally increased oxidative stress in the peripheral blood
of PD patients. In neutrophil granulocytes, PD patients
were found to have altered mitochondrial mass and mem-
brane potential, as well as increased oxidative stress.35
Prigione et al (2006) found increased total ROS levels in
PD patient PBMCs compared with controls,36 and a
recent pilot study demonstrated lower whole-blood levels
of reduced glutathione in RBD as well as PD patients.37
Given the increased mitochondrial oxidative stress
observed in the PD patient PBMCs, we further investi-
gated mitochondrial function. We found that although
PD and RBD patient PBMCs had similar oxygen con-
sumption rates, they had signiﬁcantly increased glycoly-
sis compared with controls. All the Seahorse
Extracellular Flux Analyzer experiments in this study
were performed in the presence of oligomycin and rote-
none/antimycin A to inhibit oxidative phosphorylation,
resulting in a measurement speciﬁc to glycolysis.38
Interestingly, the RBD patients resembled the PD
patients more closely than the controls, demonstrating the
predictive value of these ﬁndings and the future possibility
of establishing a glycolysis-related biomarker for the early
stages of PD. PET imaging with 18F-ﬂuorodeoxyglucose
also showed changes in brain glucose metabolism in RBD
patients compared with controls, with most brain areas
showing increased metabolism.39,40 Perturbed energy pro-
duction may be upstream of many other functional cellu-
lar defects; however, further studies are required to
establish a causal chain of events.
Furthermore, we have shown that the glycolysis dis-
ease phenotype is not driven by monocyte activation or
glucose uptake. Reduced COX4 expression may con-
tribute to defective mitochondrial function and a pro-
pensity toward glycolysis as a preferred energy
production pathway. COX4 was not signiﬁcantly
reduced in the PD patient group, suggesting that COX4
may be part of an early pathological mechanism in
these cells. Peripheral molecular changes speciﬁc to the
early stages of disease have also been observed for other
disorders.41,42 Nevertheless, this result awaits valida-
tion in a larger cohort of both PD and RBD patients.
Recently, glucose regulation and energy metabolism
have emerged as major players in neurological disease
and speciﬁcally in dopaminergic disorders. Glycolysis
pathway disruption has been identiﬁed in PBMCs from
schizophrenic patients43,44 and analysis of serum
metabolites in patients with restless legs syndrome
(RLS) showed several dysregulated pathways, including
increased lactate in both RLS and PD.45 Vascular
degeneration has also been observed in PD brain tis-
sue.46 A study complementary to our own was recently
published by Maynard et al (2015) on Alzheimer’s
patient PBMCs. Although no differences in glycolytic
reserve or MitoSox were found, reduced proton leak
and DNA repair activity in AD patients were
reported.47 Future studies investigating multiple patient
groups will aid in identifying common and diverging
PBMC pathology across neurodegenerative diseases.
Our study is among the ﬁrst to present peripheral blood
cell phenotypes of RBD patients alongside PD patients,
providing a unique opportunity to gather information
about early disease processes in humans. The signiﬁcant
changes in SOD and glycolysis in RBD patients, prior
to clinical signs of PD, demonstrate the predictive value
of including a prodromal group in studies of early dis-
ease pathology. It is interesting to note that RBD
patients can have greater phenotypes than PD patients
on some measures, most striking here in SOD activity
and COX4 expression. This is in keeping with an
emerging idea that the presence of RBD preceding PD
is potentially a more severe phenotype than PD in the
absence of RBD.48,49 It is also important to note that in
our cohort PD patients were medicated with L-dopa at a
range of doses (Table S1). We investigated the relation-
ship between L-dopa dose with the PBMC variables mea-
sured and found no effect (Fig. S7). Drug-naive patients
also did not cluster separately from other patients. How-
ever, we cannot rule out that other unreported medica-
tion could have an effect on the processes measured.
Despite the novel ﬁndings presented here, the restricted
volume of blood drawn from each participant resulted in
limited numbers of patient cells, preventing all assays
from being carried out with the same samples. For this
reason, it was not feasible to conduct protein analysis or
measure glycolysis rates using sorted PBMC cell popula-
tions, which would provide further information about the
bioenergetics of speciﬁc cell types and their relative contri-
butions, which is masked in analyses of total PBMCs.23
For each experiment we used the largest sample size possi-
ble (determined by availability of patient samples) while
maintaining age- and sex-matched groups. Further studies
are required to fully understand the relationship between
functional and gene expression changes in glycolysis and
inﬂammation in speciﬁc cell types of PBMCs in the con-
text of PD. This will be key to understanding the potential
use of PBMCs as biomarkers and therapeutic targets.
Nevertheless, despite modest sample sizes, this work dem-
onstrates signiﬁcant changes in PBMC mitochondrial
function and energy production.
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In conclusion, this study presents clear mitochondrial
and glycolysis changes in prodromal and early PD
patient blood cells. This work demonstrates PBMCs as
an easily accessible cell type with which to quantita-
tively measure early physiological changes by critically
working with human tissue.
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